ProCE Banner Activity

ADVANCE: Risk of Cardiovascular Disease and Diabetes in Treatment-Naive Patients Initiating Dolutegravir- or Efavirenz-Based ART

Slideset Download
Conference Coverage
Increases in adipose tissue and predicted 10-year risk of diabetes significantly higher with use of DTG + FTC/TAF compared with DTG + FTC/TDF or EFV/FTC/TDF in treatment-naive patients initiating ART in South Africa.

Released: March 13, 2020

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Gilead

Merck & Co., Inc.

ViiV Healthcare